醫學系泌尿學科

Keyphrases

1. Taiwan 100%
2. Prostate Cancer 63%
3. National Cohort Study 49%
4. Laparoscopic Partial Nephrectomy 43%
5. Confidence Interval 41%
6. Taipei 40%
7. Upper Tract Urothelial Carcinoma 39%
8. Androgen Deprivation Therapy 35%
9. Nephroureterectomy 31%
10. Scabies 27%
11. Tumor 25%
12. Population-based Study 24%
13. Prostate 23%
14. Transitional Cell Carcinoma 21%
15. Kidney 20%
16. Ureter 19%
17. Renal Cell Carcinoma 19%
18. Operative Time 19%
19. Prostate Cancer Patients 17%
20. Stone-free Rate 17%
21. Oncological Outcomes 17%
22. Risk Factors 17%
23. Complication Rate 17%
24. Hazard Ratio 17%
25. Radical Prostatectomy 16%
26. Urothelial Carcinoma 16%
27. Magnetic Resonance Imaging 16%
28. Prostate Cancer Cells 15%
29. Benign Prostatic Hyperplasia 15%
30. Transurethral Resection of Prostate 15%
31. Thulium Laser 15%
32. Monoamine Oxidase A (MAO-A) 15%
33. Percutaneous Nephrolithotomy 15%
34. Laparoscopic Surgery 15%
35. Patients with Prostate Cancer 14%
36. Taiwanese 14%
37. Prostate Cancer Screening 14%
38. Prostate Health Index 13%
39. Arsenic 13%
40. Bladder Cuff Excision 13%
41. Bladder Neck Contracture 13%
42. Newly Diagnosed 13%
43. High Risk 13%
44. Overall Survival 13%
45. Disease-free Survival 13%
46. Clinically Significant Prostate Cancer 13%
47. Porcine Model 13%
48. Radical Cystectomy 12%
49. Clinical Experience 12%
50. Bladder Cancer 12%
51. Elderly Patients 12%
52. Non-muscle Invasive Bladder Cancer (NMIBC) 12%
53. Systematic Meta-analysis 12%
54. After Surgery 12%
55. Extracorporeal Shock Wave Lithotripsy 12%
56. Postpartum Depression 12%
57. Pharmacokinetics 12%
58. Latanoprost 12%
59. Adjusted Hazard Ratio 11%
60. Odds Ratio 11%
61. Urolithiasis 11%
62. Varicocele 11%
63. Cancer-specific Survival 11%
64. Castration-resistant Prostate Cancer 11%
65. Hand-assisted Retroperitoneoscopic Donor Nephrectomy 10%
66. Prostate-specific Antigen 10%
67. Multivariate Analysis 10%
68. Retroperitoneoscopic 10%
69. Laparoscopy 10%
70. No Significant Difference 10%
71. Escherichia Coli 10%
72. Clinical Outcomes 10%
73. Transrectal Biopsy 10%
74. Partial Nephrectomy 10%
75. Urinary Tract Infection 10%
76. Multiparametric MRI (mpMRI) 10%
77. Ureteral Stone 10%
78. Estrogen 10%
79. National Health Insurance Research Database (NHIRD) 10%
80. Shock Wave Lithotripsy 10%
81. Laparoscopic Radical Prostatectomy 10%
82. Overexpression 9%
83. Meta-analysis 9%
84. Metastatic Castration-resistant Prostate Cancer (mCRPC) 9%
85. Autoimmune Disease 9%
86. Insufflation 9%
87. Traditional Chinese Medicine 9%
88. Younger Schoolchildren 9%
89. Breast Cancer Cells 9%
90. Recurrence-free Survival 9%
91. Renal Tissue 9%
92. Radiotherapy 9%
93. Urinary Retention 9%
94. Pneumoperitoneum 9%
95. Cell Apoptosis 9%
96. Renal Stone 9%
97. Arsenic Exposure 9%
98. Hepatoblastoma 9%
99. Endoplasmic Reticulum Stress (ER stress) 9%
100. Decoy Receptor 3 (DcR3) 9%

Medicine and Dentistry

1. Prostate Cancer 72%
2. Transitional Cell Carcinoma 66%
3. Neoplasm 49%
4. Nephroureterectomy 48%
5. Bladder 42%
6. Cohort Analysis 35%
7. Laparoscopic Surgery 29%
8. Scabies 27%
9. Partial Nephrectomy 26%
10. Kidney Stone 25%
11. Upper Urinary Tract 24%
12. Biopsy Technique 23%
13. Diseases 23%
14. Hazard Ratio 22%
15. Prostatectomy 22%
16. Clear Cell Renal Cell Carcinoma 22%
17. Lithotripsy 21%
18. Prostate Specific Antigen 20%
19. Operation Duration 19%
20. Odds Ratio 19%
21. Cystectomy 18%
22. Transrectal Ultrasonography 18%
23. Surgery 18%
24. Transurethral Resection 17%
25. Urinary System 17%
26. Nephrectomy 17%
27. Recurrent Disease 16%
28. Bleeding 16%
29. Overall Survival 16%
30. Thulium 15%
31. Ligation 15%
32. Magnetic Resonance Imaging 15%
33. Prostate Biopsy 15%
34. Percutaneous Nephrolithotomy 15%
35. Ureter 14%
36. Androgen Deprivation Therapy 13%
37. Bladder Neck Stenosis 13%
38. Cell Signaling Pathway 12%
39. Computer Assisted Tomography 12%
40. Castration Resistant Prostate Cancer 12%
41. Shock Wave 12%
42. Malignant Neoplasm 12%
43. Incision 11%
44. Disease Free Survival 11%
45. Pelvis 11%
46. Infection 11%
47. Retrospective Study 11%
48. Testes 10%
49. Proportional Hazards Model 10%
50. Prostate Hypertrophy 10%
51. Radiation Therapy 9%
52. Extracorporeal Shock Wave Lithotripsy 9%
53. Urinary Retention 9%
54. Adrenalectomy 9%
55. Multivariate Analysis 9%
56. Elderly Patient 9%
57. Urinary Tract 9%
58. Bladder Cancer 9%
59. Programmed Cell Death 9%
60. Mitochondrion 9%
61. Ureter Stone 9%
62. Urothelial Cancer 9%
63. Metastatic Carcinoma 8%
64. Non Muscle Invasive Bladder Cancer 8%
65. Pheochromocytoma 8%
66. Urinary Tract Infection 8%
67. Kidney Function 8%
68. Hormone Therapy 8%
69. Peroperative Complication 8%
70. Cancer Diagnosis 8%
71. Amine Oxidase (Flavin Containing) Isoenzyme A 8%
72. Surgeon 7%
73. Emergency Department 7%
74. Survival Rate 7%
75. Body Mass Index 7%
76. Prevalence 7%
77. Messenger RNA 7%
78. Intraocular Pressure 7%
79. Mitogen Activated Protein Kinase 3 7%
80. Cancer Specific Survival 7%
81. Kidney Blood Flow 7%
82. Pneumoretroperitoneum 7%
83. Retreatment 6%
84. Autoimmune Disease 6%
85. Diabetes Mellitus 6%
86. Comorbidity 6%
87. Postoperative Complication 6%
88. Adrenal Incidentaloma 6%
89. Staghorn Stone 6%
90. Pneumoperitoneum 6%
91. Adrenal Tumor 6%
92. Meta-Analysis 6%
93. Systematic Review 6%
94. Gleason Score 6%
95. Bladder Neck 6%
96. Recurrence Free Survival 6%
97. Cancer Staging 6%
98. Diagnosis 6%
99. Holmium 6%
100. Orchitis 6%